Lakewood-Amedex Stock Price, News & Analysis

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing antimicrobial drug candidates for infectious diseases. The company’s research is centered on the Bisphosphocin® class, a novel class of fast-acting, broad-spectrum antimicrobials discovered by Lakewood-Amedex and intended to address bacterial infections, including strains associated with antimicrobial resistance such as MRSA and VRE. Its common stock trades on the Nasdaq Capital Market under the symbol LABT following an April 2026 direct listing.

Antimicrobial platform and lead compound

The company’s lead compound, Nu-3, is being developed as a topically delivered antimicrobial treatment for infected diabetic foot ulcers. Lakewood-Amedex describes Nu-3 as part of its Bisphosphocin platform. Reported in vitro data for the class indicate rapid bacterial killing through pH- and concentration-dependent destabilization of bacterial cell membranes. The platform is also being explored in preclinical studies for potential use in complicated urinary tract infection and pulmonary infections.

Lakewood-Amedex’s operating model is based on advancing proprietary antimicrobial compounds through research, preclinical work, clinical development, and regulatory preparation. As a clinical-stage biotechnology issuer, the company’s durable business profile is defined by its drug-development pipeline rather than commercial product sales.

Public company status

Lakewood-Amedex Biotherapeutics is incorporated in Nevada and maintains principal executive offices in University Park, Florida. Its SEC registration materials identify the company within pharmaceutical preparations. Public-company disclosures for LABT cover securities registration, corporate governance, board composition, capital structure, business risks, and updates related to its antimicrobial development programs.